Haplotype Effects on Matrix Metalloproteinase-1 Gene Promoter Activity in Cancer Cells

Pearce, Eve G.; Laxton, Ross C.; Pereira, Andresa Costa; Ye, Shu

doi:10.1158/1541-7786.mcr-06-0139

Cited by 14 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Matrix metalloproteinases (MMPs) are a large family of zinc-dependent enzymes that cleave extracellular matrix (ECM) proteins during cancer invasion [35][36][37]. Previous reports implicated that MMP-1 was one of the most highly upregulated MMPs in breast cancer and involved in invasion and metastasis [38,39].…”

Section: Discussionmentioning

confidence: 99%

A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo

Lin

Huo

Wang

et al. 2011

Cancer Immunol Immunother

View full text Add to dashboard Cite

Cysteine-rich protein 61(CCN1/Cyr61) has been implicated as an important mediator in proliferation and metastasis of breast cancer, which indicated that blockage of Cyr61 might be a potent target for breast cancer treatment. However, the antitumor effect of anti-Cyr61 antibodies on breast cancer in vivo has not been reported so far. In this study, we reported the effect and likely mechanism of generated anti-human Cyr61 monoclonal antibodies (mAb) on Cyr61 high expression line MDA-MB-231, known as a highly malignant and invasive human breast cancer cell line, at aspects of proliferation and migration in vitro and in vivo. We found the mAb, denoted as 093G9, revealed inhibitory effects on MDA-MB-231 cell proliferation, migration, and invasion through downregulation of both AKT and ERK phosphorylation in vitro compared with its isotype control. 093G9 also showed significant efficacy on suppressing primary tumor growth and spontaneous lymph node metastasis in in vivo mouse model. The specific epitope recognized by 093G9 was identified to be (140)LPNLGCP(146), adjacent to the VWC domain of Cyr61 by Ph.D.-C7C phage library display system. Our study provides direct evidence that Cyr61 can be a potent therapeutic target for patients who bear high Cyr61 expression breast cancer. Furthermore, the mAb, 093G9 developed in our laboratory, has shown a promising therapeutic characteristic in breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo

Lin

Huo

Wang

et al. 2011

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…The transcriptional activation of MMP1 is influenced by a SNP located at position −1607 (rs1799750) in the MMP1 promoter region [18]. Specifically, other SNPs [−519 A > G (rs1144393), −422A > T (rs475007), −340 A > G (rs514921), and −320T > C (rs494379)] in the MMP1 promoter region exhibited haplotype effects on MMP1 activity [19]. Furthermore, several of these SNPs in the MMP1 promoter region were associated with susceptibility to coronary artery disease, posterior tibial tendinopathy, and IPF [20–23].…”

Section: Introductionmentioning

confidence: 99%

MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy

Liu

Tang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Matrix metalloproteinase-1 (MMP-1) has been implicated in several inflammatory and fibrotic diseases. We hypothesized that genetic variations in the MMP1 promoter region are associated with risk of radiation-induced lung injury (RILI). A cohort of 251 lung cancer patients was genotyped for five single nucleotide polymorphisms in the MMP1 promoter region. We found that rs1144393 AG/GG was strongly correlated with an increased occurrence of grade ≥ 2 RILI (p = 0.002). Additionally, patients with the rs1144393 AG/GG genotypes exhibited higher MMP-1 expression than patients with the AA genotype in lung tissues (n = 28, p = 0.022) and plasma samples (n = 40, p = 0.018). Our results indicated that rs1144393 in the MMP1 promoter region can be a predictor of grade ≥ 2 RILI in lung cancer patients treated with thoracic radiation.

show abstract

“…Groups have widely studied the association of this variation with risk of development or progression of various cancers [15–18]. Specifically, −1607 1G/2G and six other SNPs (−839G > A, −755T > G, −519A > G, −422A > T, −340A > G, and −320T > C) in the MMP1 promoter region exhibited haplotype effects on MMP1 promoter activity [19]. We recently reported the significant associations of several of these SNPs in the MMP1 promoter region with cutaneous melanoma (CM) susceptibility [20].…”

Section: Introductionmentioning

confidence: 99%

Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression

Liu¹,

Wei²,

Gershenwald³

et al. 2012

Melanoma Research

View full text Add to dashboard Cite

Recently, we reported on the associations of seven single-nucleotide polymorphisms (SNPs) in the promoter region of MMP1 gene with susceptibility to cutaneous melanoma (CM). Considering the reported correlation between MMP1 expression and melanoma progression, we hypothesized that these promoter SNPs might affect CM progression and prognosis. In this study, we examined the associations of the seven SNPs with overall survival as well as six clinicopathologic factors in 754 patients with CM. After adjustment for 11 covariates, we observed significant association of the SNP −422A > T (rs475007) with ulceration status (P = 0.012), primary tumor thickness (P = 0.040), and anatomic site (P = 0.030). We also observed significant association of the SNP −755T > G (rs498186) with ulceration status (P = 0.038) and anatomic site (P = 0.003). Two SNPs −839G > A and −519A > G were marginally associated with primary tumor thickness, ulceration status, and anatomic site. Furthermore, the frequency of haplotype 2G-G-G-A-A-G-T was higher in patients with ulceration (odds ratio [OR] = 2.18, 95% confidence interval [CI] 1.08–4.40, P = 0.030) than that in those without ulceration. However, we did not find significant associations of these SNPs with overall survival and other clinical factors. Since primary tumor thickness and ulceration status are two important indicators of tumor progression and have significant associations with melanoma prognosis, our results suggested that these promoter SNPs in MMP1 might have potential effects on melanoma progression and prognosis by influencing related clinical factors.

show abstract

Haplotype Effects on Matrix Metalloproteinase-1 Gene Promoter Activity in Cancer Cells

Cited by 14 publications

References 22 publications

A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo

A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo

MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy

Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression

Contact Info

Product

Resources

About